戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  525 mg/day is the recommended dose for oral enzastaurin.
2 cal studies, and clinical study results with enzastaurin.
3 e basis of plasma exposures and safety data, enzastaurin 525 mg once daily is the recommended phase I
4                                              Enzastaurin - a novel oral antitumor agent that selectiv
5                                              Enzastaurin, a PKCbeta inhibitor, blocked PKCbeta activi
6 rve as a reliable pharmacodynamic marker for Enzastaurin activity.
7 e II trial tested the efficacy and safety of enzastaurin added to a standard carboplatin/paclitaxel c
8 nducted to determine the recommended dose of enzastaurin, an oral protein kinase C beta (PKCbeta) inh
9                                              Enzastaurin, an oral serine/threonine kinase inhibitor,
10                  In addition, treatment with Enzastaurin and AR-A014418 decreased the mRNA levels and
11                              Total analytes (enzastaurin and its metabolites) exposure increased with
12              Treatment with a combination of Enzastaurin and the GSK3 inhibitor AR-A014418 resulted i
13 mpounds, including bortezomib, lenalidomide, enzastaurin, and adaphostin.
14 y and demonstrate that the PKCbeta inhibitor enzastaurin, and the clinically available anti-hypertens
15 nd the clinical value of the repurposed drug enzastaurin as a potential novel therapeutic strategy to
16               These results demonstrate that enzastaurin, at clinically achievable concentrations, in
17  various advanced cancers and suggested that enzastaurin can be safely used long term in combination
18                                              Enzastaurin combined with GSK3 inhibitors demonstrated a
19                                 Furthermore, enzastaurin demonstrated additive cytotoxicity in combin
20                                              Enzastaurin displays pro-apoptotic properties against a
21                                 Furthermore, enzastaurin downregulated AKT activity and its downstrea
22 ed the novel, orally available PKC-inhibitor enzastaurin for its anti-MM activity.
23 iers in vitro and tested the repurposed drug enzastaurin for its propensity to improve experimental p
24 e PKCbeta-selective small molecule inhibitor enzastaurin had a similar effect.
25                         These data show that Enzastaurin has a direct antitumor effect and that Enzas
26                         Herein, we show that Enzastaurin has a direct effect on human tumor cells, in
27 KC) isoforms by the small molecule inhibitor enzastaurin has shown promising preclinical activity in
28              Our studies therefore show that enzastaurin has significant antitumor activity in WM bot
29  survival, and angiogenesis are abrogated by enzastaurin in an in vivo xenograft model of human MM.
30 olerability and survival data, evaluation of enzastaurin in combination with cytotoxic drugs is warra
31 results directly led to a clinical trial for Enzastaurin in CTCL in which it was well tolerated and s
32                           Further studies of enzastaurin in DLBCL are warranted.
33 ficacy of the orally available PKC inhibitor enzastaurin in MM and strongly support its clinical eval
34                   A recent phase II study of enzastaurin in patients with relapsed or refractory diff
35            The brain penetrant PKC inhibitor enzastaurin, in combination with paxalisib, synergistica
36 e II study of a potent inhibitor of PKCbeta, enzastaurin, in patients with relapsed or refractory DLB
37 at the protein kinase C (PKC) beta inhibitor Enzastaurin increases apoptosis in malignant lymphocytes
38                                              Enzastaurin induced dose-dependent apoptosis at 48 hours
39                                              Enzastaurin-induced cell death involved caspase-3-activa
40 ore, accumulated beta-catenin contributes to enzastaurin-induced cell death.
41                                              Enzastaurin inhibited Akt phosphorylation and Akt kinase
42                                Consequently, enzastaurin inhibits proliferation, survival, and migrat
43                        Our results show that enzastaurin is an effective chemopreventive agent in a m
44                                              Enzastaurin is an oral serine/threonine kinase inhibitor
45 ng synergistic cytotoxicity is observed when enzastaurin is combined with bortezomib and moderate syn
46            Based on these and previous data, enzastaurin is currently under clinical investigation in
47                                              Enzastaurin is emerging as a promising new antitumor tre
48                                              Enzastaurin is well tolerated up to 700 mg/d.
49                                              Enzastaurin (LY317615) was initially developed as an ant
50 arget for colon cancer chemoprevention using enzastaurin (LY317615), a PKCbeta-selective inhibitor, i
51             The PKCbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses angiogenesis and
52 o PI3K/AKT activation, but it is unknown how enzastaurin may interfere with signaling through this pa
53 evention and the PKCbeta-selective inhibitor enzastaurin may represent an effective chemopreventive a
54                                              Enzastaurin not only inhibits protein kinase Cbeta activ
55                     Two deaths, unrelated to enzastaurin, occurred.
56 he effects of the PKCbeta-specific inhibitor enzastaurin on the survival of B cells from mice with lu
57          We have investigated the effects of enzastaurin on the viability of the cutaneous T-cell lym
58                                 In addition, enzastaurin overcame tumor cell growth induced by cocult
59  of chemotherapy (paclitaxel/carboplatin +/- enzastaurin [PCE/PC]) followed by maintenance therapy (e
60 n [PCE/PC]) followed by maintenance therapy (enzastaurin/placebo).
61 a-catenin decreased the cytotoxic effects of Enzastaurin plus AR-A014418.
62                                 We find that enzastaurin potently reduces azoxymethane-induced colon
63 Sle mice with the PKCbeta-specific inhibitor enzastaurin prevented the development of lupus.
64                 Inhibition of PKCbetaII with enzastaurin reduced A549 cell proliferation by >60% (48
65                               Biochemically, enzastaurin reduces expression of the PKCbetaII- and bet
66                                              Enzastaurin reversed PH in the Sugen5416/hypoxia/normoxi
67 ulation of Fas and DR5, and PKCbeta shRNA or enzastaurin reversed this effect.
68                                    Moreover, enzastaurin sensitized a variety of human tumor cell lin
69                                              Enzastaurin specifically inhibits phorbol ester-induced
70  reports, these data support the notion that Enzastaurin suppresses tumor growth through multiple mec
71 d smooth muscle cell dysfunction, rescued by enzastaurin through a dual mechanism: upregulation of FH
72 ractory diffuse large B-cell lymphoma showed enzastaurin to be associated with prolonged freedom from
73 istance, the authors added the PKC inhibitor enzastaurin to their drug combination and showed that th
74                             Oral dosing with Enzastaurin to yield plasma concentrations similar to th
75 hibition of tumor growth was observed in the enzastaurin-treated mice (P = .028).
76                                              Enzastaurin treatment also suppresses GSK3beta phosphory
77                                              Enzastaurin treatment also suppresses the phosphorylatio
78 ive B cells as well as the in vivo effect of enzastaurin treatment on the development of lupus in Sle
79 aurin has a direct antitumor effect and that Enzastaurin treatment suppresses GSK3beta phosphorylatio
80                  As in cultured tumor cells, Enzastaurin treatment suppresses the phosphorylation of
81                                              Enzastaurin-treatment decreased cell viability, increase
82                       This phase II trial of enzastaurin was conducted to determine the 6-month progr
83                                              Enzastaurin was taken orally once daily until disease pr
84                               Treatment with enzastaurin was well-tolerated and associated with prolo
85 certain a means of improving the efficacy of Enzastaurin, we investigated complementary signaling pat
86 age, 58 years) received at least one dose of enzastaurin, with a median of two cycles (range, one to